BC Extra | Jan 2, 2020
Politics & Policy

Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

The latest round of increases in the list prices of drugs highlights how pending bipartisan legislation could force biopharma companies to rethink their business models. In what has become a predictable biannual event, manufacturers announced...
BC Innovations | Jul 11, 2019
Translation in Brief

PARP inhibitors plus senolytics: a double hit on cancer

A new approach to synthetic lethality aims to overcome resistance to PARP inhibitors by pairing them with senolytic agents, marking one of the first moves beyond DNA damage repair combinations. PARP inhibitors hinder DNA damage...
BC Extra | Jul 3, 2019
Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches. One of the main limitations of CAR T cell therapy...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Innovations | Feb 26, 2019
Distillery Therapeutics

Cancer

INDICATION: Bladder cancer; breast cancer; colorectal cancer; melanoma; sarcoma Mouse studies suggest inhibiting DDR2 could enhance the efficacy of anti-PD-1 therapies for bladder, breast and colorectal cancers, melanoma and sarcoma. In mouse models of bladder...
BC Week In Review | Feb 15, 2019
Clinical News

EC approves BMS's Sprycel for pediatric ALL

The European Commission approved Sprycel dasatinib from Bristol-Myers Squibb Co. (NYSE:BMY) in combination with chemotherapy to treat pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The approval covers both tablet and...
BC Innovations | Jan 8, 2019
Distillery Therapeutics

Neurology

INDICATION: Anxiety Mouse studies suggest depleting senescent cells could help treat obesity-induced anxiety. In a transgenic mouse model of obesity expressing the senescence marker human CDKN2A, a tool compound that depletes CDKN2A-positive cells decreased anxiety-like...
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
BC Week In Review | Jan 4, 2019
Clinical News

FDA approves BMS's Sprycel for pediatric ALL

FDA approved an sNDA from Bristol-Myers Squibb Co. (NYSE:BMY) to expand the label of Sprycel dasatinib to include treatment of pediatric patients ages one and older with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The...
BC Extra | Dec 22, 2018
Politics & Policy

Partial shutdown sees 41% of FDA staff furloughed

FDA has furloughed almost half its staff after the U.S. government partially shut down early Dec. 22, potentially slowing approvals and stalling advisory committee meetings. Commissioner Scott Gottlieb confirmed in a tweet Friday that FDA...
Items per page:
1 - 10 of 270